Company / Total Assets
Charles River Laboratories Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$7.1B
FY2025
5-year range
$7.0B / $8.2B
FY2021-FY2025
Trend
-5.2%
vs FY2024
Sector context
#41 of 160
Health Care
What the data says
At $7.1B, Charles River Laboratories's total assets ranks #41 of 160 in the Health Care sector. Declined from $8.2B to $7.1B over the past 2 years.
Based on SEC 10-K filings.
$7.1B in FY2025 with a 5-year CAGR of +5.4%.
Declined from $8.2B to $7.1B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -2.1%
- 5-Year CAGR
- +5.4%
- 10-Year CAGR
- -
Sector benchmark
#41 of 160 in Health CareTop 26% of 160This company $7.1B Sector average $14.8B
▼
-51.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.4%, indicating consistent growth.
- In FY2025, total assets decreased 5.2% year-over-year.
- Ranks #41 out of 160 companies in the Health Care sector.
- Peak total assets was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.1B | -5.2% |
| FY2024 | $7.5B | -8.1% |
| FY2023 | $8.2B | +7.8% |
| FY2022 | $7.6B | +8.2% |
| FY2021 | $7.0B | +27.9% |
| FY2020 | $5.5B | +17.0% |
| FY2019 | $4.7B | +21.7% |
| FY2018 | $3.9B | +31.6% |
| FY2017 | $2.9B | +8.0% |
| FY2016 | $2.7B | +31.1% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026